anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a therapeutic agent for viral diseases, containing Cordyceps sinensis Sacc. and capable of manifesting therapeutic effects without causing adverse effects on hardly treatable diseases such as leukemia or AIDS. SOLUTION: This therapeutic agent for viral diseases containing Cordyceps sinensis Sacc. is obtained by pulverizing a dried material of the Cordyceps sinensis Sacc. or its fermented spore into a powder with a pulverizer, then suitably blending an excipient, a binder, a disintegrating agent, etc., therewith, uniformly mixing the ingredients, compression molding and formulating the resultant mixture into a pharmaceutical preparation of a tablet. The dose thereof is 3-9g at a time (50-150mg/kg) expressed in terms of weight of the technical product of the Cordyceps sinensis Sacc. for an adult. When the fermented spore is used, the daily dose is preferably 0.25-1.5g and administered about three times. The daily frequency of administration is preferably 2-4 times.  The Cordyceps sinensis Sacc. just after collection is in a state of one to several shot out mushroom buds having 4-10cm length from the head of an insect body having 3-5cm length and 0.3-0.8cm diameter and impurities sticking thereof are removed to dry the resultant material. The pure spore is separated from the technical product of the Cordyceps sinensis Sacc., cultured in a liquid, proliferated, fermented and dried at 60-80 deg.C. The resultant solidified and fermented spore can be used.
Disclosed is a screening method which can screen for a prophylactic and/or therapeutic agent for a disease associated with a hepatitis C virus efficiently in a simple manner.  Also disclosed is a prophylactic and/or therapeutic agent for a disease associated with a hepatitis C virus, which is produced by the method. The screening method for a prophylactic and/or therapeutic agent for a disease associated with a hepatitis C virus comprises the step of evaluating the inhibitory activity of a substance of interest on the interaction between a hepatitis C virus core protein and PA28γ.  The method may be conducted by employing the transcriptional activity of a lipid metabolism regulation factor as a measure.  The substance to be tested in the method may have an inhibitory activity on the expression or function of PA28γ gene.  The disease associated with a hepatitis C virus includes hepatitis C, fatty liver, acute hepatitis, chronic hepatitis, cirrhosis, liver cancer and an insulin-resistance disease.  The method is extremely useful as a method for producing an agent having an excellent prophylactic and/or therapeutic effect particularly on fatty liver or liver cancer with efficiency.
Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m\^2) on day 1 and fludarabine phosphate (age \< 70: 25 mg/m\^2/day; age \>= 70: 20 mg/m\^2/day) IV piggyback over 30 minutes or PO (32 mg/m\^2/day) and cyclophosphamide IV (age \< 70: 250 mg/m\^2/day; age \>= 70: 150 mg/m\^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
Despite the advent of precision therapy for breast cancer (BRCA) treatment, some individuals are still unable to benefit from it and have poor survival prospects as a result of the disease's high heterogeneity. Cell senescence plays a crucial role in the tumorigenesis, progression, and immune regulation of cancer and has a major impact on the tumor microenvironment. To find new treatment strategies, we aimed to investigate the potential significance of cell senescence in BRCA prognosis and immunotherapy. We created a 9-gene senescence-related signature. We evaluated the predictive power and the role of signatures in the immune microenvironment and infiltration. In vitro tests were used to validate the expression and function of the distinctive critical gene ACTC1. Our risk signature allows BRCA patients to receive a Predictive Risk Signature (PRS), which may be used to further categorize a patient's response to immunotherapy. Compared to conventional clinicopathological characteristics, PRS showed strong predictive efficacy and precise survival prediction. Moreover, PRS subgroups were examined for altered pathways, mutational patterns, and possibly useful medicines. Our research offers suggestions for incorporating senescence-based molecular classification into risk assessment and ICI therapy decision-making.
BACKGROUND: Individuals diagnosed with hemifacial spasm (HFS) frequently undergo noticeable alterations in their facial appearance. Such changes can detrimentally influence both their physical and psychological well-being. While prior studies have identified self-esteem and fear of negative evaluation (FNE) as key elements in social anxiety, their role in studies concerning body image and its correlation with social anxiety has been seldom explored. This research seeks to explore how self-esteem and FNE concurrently mediate the relationship between body image and social anxiety among Chinese individuals with HFS.
METHODS: Chinese patients with HFS (n=151) completed a cross-sectional questionnaire on the first day of admission that assessed body image, social anxiety, self-esteem, and FNE over the past week. Path analysis was used to test the hypothesis of the mediation model.
RESULTS: The hypothesized model showed that FNE was positively correlated with body image and social anxiety, while negative associations were found among body image, self-esteem and social anxiety. Self-esteem and FNE play a mediating role between body image and social anxiety.
CONCLUSION: Our findings suggest that self-esteem and FNE may be important psychological pathways that affect body image and social anxiety in Chinese patients with HFS. Supplementing mental health services that help increase self-esteem and reduce FNE should be considered to improve the psychological quality of patients with HFS.
Oxygen toxicity is one of the major risk factors in the development of the chronic lung disease or bronchopulmonary dysplasia in premature infants. Using proteomic analysis, we discovered mitochondrial aldehyde dehydrogenase (mtALDH or ALDH2) was down-regulated in neonatal rat lung after hyperoxic exposure. To study the role of mtALDH in hyperoxic lung injury, we overexpressed mtALDH in human lung epithelial cells (A549) and found that mtALDH significantly reduced hyperoxia-induced cell death. Compared to control cells (Neo-A549), the necrotic cell death in mtALDH overexpressing cells (mtALDH-A549) decreased from 25.3% to 6.5%, 50.5% to 9.1% and 52.4% to 15.06% after 24-, 48- and 72-hour hyperoxic exposure, respectively. The levels of intracellular and mitochondria-derived reactive oxygen species (ROS) in mtALDH-A549 cells after hyperoxic exposure were significantly lowered compared to Neo-A549 cells. mtALDH overexpression significantly stimulated extracellular signal regulated kinase (ERK) phosphorylation under normoxic and hyperoxic conditions. Inhibition of ERK phosphorylation partially eliminated the protective effect of mtALDH in hyperoxia-induced cell death, suggesting ERK activation by mtALDH conferred cellular resistance to hyperoxia. mtALDH overexpression augmented Akt phosphorylation and maintained the total Akt level in mtALDH-A549 cells under normoxic and hyperoxic conditions. Inhibition of PI3K activation by LY294002 in mtALDH-A549 cells significantly increased necrotic cell death after hyperoxic exposure, indicating that PI3K/Akt activation by mtALDH played an important role in cell survival after hyperoxia. Taken together, these data demonstrate that mtALDH overexpression attenuates hyperoxia-induced cell death in lung epithelial cells through reduction of ROS, activation of ERK/MAPK and PI3K/Akt cell survival signaling pathways.
MICARDIS HCT tablets are a combination of telmisartan, an orally active angiotensin II antagonist acting on the AT1 receptor subtype, and hydrochlorothiazide, a diuretic.

Telmisartan, a non-peptide molecule, is chemically described as 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid. Its empirical formula is C33H30N4O2, its molecular weight is 514.63, and its structural formula is:

Telmisartan is a white to slightly yellowish solid. It is practically insoluble in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except insoluble in hydrochloric acid), and soluble in strong base.

Hydrochlorothiazide is a white, or practically white, practically odorless, crystalline powder with a molecular weight of 297.74. It is slightly soluble in water, and freely soluble in sodium hydroxide solution. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2, and its structural formula is:

MICARDIS HCT tablets are formulated for oral administration in three combinations of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg telmisartan and hydrochlorothiazide, respectively. The tablets contain the following inactive ingredients: sodium hydroxide, meglumine, povidone, sorbitol, magnesium stearate, lactose monohydrate, microcrystalline cellulose, maize starch, sodium starch glycolate. As coloring agents, the 40 mg/12.5 mg and 80 mg/12.5 mg tablets contain ferric oxide red, and the 80 mg/25 mg tablets contain ferric oxide yellow. Micardis® HCT (telmisartan and hydrochlorothiazide) tablets are hygroscopic and require protection from moisture.
For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
Otitis Media Trial of Clarithromycin vs. Oral Cephalosporin 

In a controlled clinical trial of pediatric patients with acute otitis media performed in the United States, where significant rates of beta-lactamase producing organisms were found, clarithromycin was compared to an oral cephalosporin. In this trial, strict evaluability criteria were used to determine clinical response. For the 223 patients who were evaluated for clinical efficacy, the clinical success rate (i.e., cure plus improvement) at the post-therapy visit was 88% for clarithromycin and 91% for the cephalosporin. 

In a smaller number of patients, microbiologic determinations were made at the pre-treatment visit. The presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) are shown in Table 16.

Otitis Media Trials of Clarithromycin vs. Antimicrobial/Beta-lactamase Inhibitor 

In two other controlled clinical trials of acute otitis media performed in the United States, where significant rates of beta-lactamase producing organisms were found, clarithromycin was compared to an oral antimicrobial agent that contained a specific beta-lactamase inhibitor. In these trials, strict evaluability criteria were used to determine the clinical responses. In the 233 patients who were evaluated for clinical efficacy, the combined clinical success rate (i.e., cure and improvement) at the post-therapy visit was 91% for both clarithromycin and the control. 

For the patients who had microbiologic determinations at the pre-treatment visit, the presumptive bacterial eradication/clinical cure outcomes (i.e., clinical success) are shown in Table 17.
This is a longitudinal study to examine access to care, perceived quality of life, member satisfaction and patient-reported outcomes among HIV+ adult Medicaid recipients. Special Needs Plans represent a new approach to managed care tailored to patients with complicated medical and psychosocial problems,requiring a high level of service. These plans combine HIV primary and specialty care, mental health services, substance use treatment, care for dependent children and social services into a single comprehensive program that also includes comprehensive case management and other provisions to retain patients in care. Special Needs Plans represent an alternative to both, Medicaid Fee for Service (FFS) and to mainstream Medicaid managed care.Seven different Special Needs Plans will be implemented, serving in New York City and the surrounding suburbs. A separate non-profit corporation administers each SpecialNeeds Plan. Each plan encompasses a network of hospitals, providers, and communitybased organizations. Although all plans offer many of the same basic services, they differ in terms of organization and coordination of care, approaches to case management,specific program enhancements (e.g., patient education, wellness programs, or complementary medicine) and special provisions to meet the needs of subgroups of patients (e.g., women, substance users, young gay men, Latinos). The HIV Special Needs Plans represent an innovation in health service delivery and financing that is being evaluated as a national model for Medicaid service delivery by the federal government, including HRSA and HCFA. This protocol represents a component of that evaluation,from the patients' perspective.This study is being conducted in collaboration with the New York State Department of Health (NYSDOH) AIDS Institute. As a component of their Quality Management and Improvement Programs, Special Need Plans have agreed to assist with recruitment of participants to this evaluation. We will recruit 120 patients sampled from each of the six plans and follow these patients for initially a year with a possibility of continuing to interview them for up to two years. We will also recruit a sample of 360 current Medicaid fee for service patients to serve as comparison group. This sampling strategy will allow us to examine experiences in care and outcomes for different subgroups of patients within the plans, distinguish the affects of service differences among the plans and compare different plan enrollees to similar patients who remain in the Medicaid FFS program. Our longitudinal design will also permit us to examine prospective influences on comparison group patients' decisions to switch their coverage from Medicaid FFS to Special Needs Plans.
Disclosed are oxygen-containing particles, a manufacturing method therefor, and a use thereof. The oxygen-containing particles comprise a carrier that is safe for the human body and has a large number of micropores or pores distributed on the surface. The oxygen-containing particles further comprise a peroxide crystal attached to the surface of the micropores or pores of the carrier. The oxygen-containing particles in the present invention have the advantage of having microparticles in addition to a slow and controllable release of oxygen. The oxygen-containing particles can achieve local or systemic oxygen supply during embolization, implantation, perfusion and other operations. Furthermore, the oxygen-containing particles can also be used alone to supply oxygen for patients with pulmonary dysfunction.
The invention relates to biotechnology. The protein-polypeptide complex which has a tissue-specific regenerative, reparative and rejuvenating effect on skin tissue is produced from nerve and skin tissues of embryos of hoofed agricultural animals within a gestation period from the middle of the first trimester to the middle of the final trimester of pregnancy by homogenizing said tissue in a buffer solution with simultaneous extraction in the presence of reversible proteolysis inhibitors, non-ionic detergents and solubilizers at a pH of 5.2-8.5. The homogenate produced is centrifuged and filtered. The proteins are separated out on a chromatography column using an anion-exchange medium. The fractions produced are combined and subjected to sterilizing filtration. The complex comprises negatively charged, weakly acid, neutral proteins and polypeptides having molecular masses of from 0.5 to 200 kDa. The complex is characterized by an absorption peak at a wavelength of 215±5 nm upon plotting of the ultraviolet spectrum in a wavelength range of from 200 to 500 nm. The pharmaceutical composition comprises, as active ingredient, the protein-polypeptide complex in a concentration of 0.01-2.0 mg/ml, polynucleotides in the form of a sodium salt of deoxyribonucleic acid, and a pharmaceutically acceptable diluent.
Methods for homologously recombining an exogenous nucleic acid into a target cell genome of a multicellular organism, e.g., an animal, are provided. In t he subject methods, a targeting vector that includes a linearizing endonuclease site, e.g., a recombinase recognition site, and a homologous recombination integrating element, is contacted with the multicellular organism, e.g., via systemic or local administration, such that the target cell(s) of the multicellular organism takes up the targeting vector. The targeting vector i s one that has been linearized by a linearizing endonuclease, e.g., a recombinase, at some point prior to the homologous recombination event, e.g. , prior to or after contact with the multicellular organism. Following uptake by the target cell(s), the integrating element then homologously recombines int o the target cell genome from the linearized targeting vector. Also provided a re targeting vectors, systems and kits for use in practicing the subject method s.
BACKGROUND AND AIM: Potassium-competitive acid blockers more strongly suppress the gastric acid barrier than proton pump inhibitors and cause dysbiosis. However, preventive measures in this regard have not been established. We aimed to evaluate whether 1-kestose, a known prebiotic, was effective at alleviating dysbiosis caused by potassium-competitive acid blockers.
METHODS: Patients scheduled to undergo endoscopic resection for superficial gastroduodenal tumors were enrolled and randomized 1:1 to receive either 1-kestose or placebo. All patients were started on potassium-competitive acid blocker (vonoprazan 20 mg/day) and took 1-kestose 10 g/day or placebo (maltose) 5 g/day for 8 weeks. The primary outcome was the effect of 1-kestose on potassium-competitive acid blocker-induced alterations in the microbiome. The fecal microbiome was analyzed before and after potassium-competitive acid blocker treatment via MiSeq (16S rRNA gene V3-V4 region).
RESULTS: Forty patients were enrolled, and 16 in each group were analyzed. In the placebo group, the Simpson index, an alpha diversity, was significantly decreased and relative abundance of Streptococcus was significantly increased by 1.9-fold. In the kestose group, the Simpson index did not change significantly and relative abundance of Streptococcus increased 1.3-fold, but this was not a significant change. In both groups, no adverse events occurred, ulcers were well healed, and pretreatment and posttreatment short-chain fatty acid levels did not differ.
CONCLUSIONS: The potassium-competitive acid blocker caused dysbiosis in the placebo group; this effect was prevented by 1-kestose. Thus, 1-kestose may be useful in dysbiosis treatment.
The investigators intend to recruit 56 patients with suspected sepsis who attend the Emergency Department. The investigators want to use a device to monitor tissue oxygen levels when they first come into the Emergency Department as well as the change in tissue oxygen levels when a tourniquet is applied for 3 minutes. The investigators will take novel blood tests when the patient is having their routine bloods. Finally, the investigators will use a special camera to take specialised pictures of the small blood vessels under the tongue which will show blood flow through these vessels. The investigators will follow the recruited patients and determine if our extra data is better at determining who needs critical care. A significant proportion of patients may be too unwell or too distressed to consent to be part of this study. At the earliest opportunity, the investigators will ask patients when they have been stabilised and are able to give consent. If they say no, they will be removed from the study and their care will not be affected by this decision.

The results could help us identify septic shock as early as possible so that these unwell patients are identified early and get the correct treatment they need. This could mean starting advanced treatments usually found in the Intensive Care Unit very early on in a patient's journey.
This application relates to compositions comprising cellulose nanocrystals (CNCs) and photosensitizer molecules conjugated to the CNCs. In some embodiments the compositions generate reactive oxygen when exposed to light. Methods of preparing the compositions and using the compositions or formulations containing the compositions as biocidal disinfectants are also described. In some embodiment the photosensitizer molecules comprise cationic dyes with acidic protons, such as azure A. In some embodiments the CNC and photosensitizer molecules are coupled together using a pH mediated synthetic protocol whereby the photosensitizer molecules are first dispersed in an acidic suspension of oxidized CNCs and the suspension is then adjusted to an alkaline pH to facilitate photosensitizer fixation. In some embodiments, photobactericidal potency of the composition is significantly more toxic to a broad spectrum of bacteria than the light-activated photosensitizer molecules in a non-conjugated free form. The compositions can be incorporated in various formulations for photobiocidal applications, including aqueous solutions, film-forming polymers such as paints, and hydrogels.
The present invention discloses external medicinal liquor for treating fracture, which belongs to a Chinese herbal medicine preparation for treating fracture. The external medicinal liquor is prepared from the following medicines: safflower, common prism tuber, zedoary, sinomenium acutum, glabrousleaf pittosporum root, dahurian angelica, shinyleaf pricklyash root, radix dipsaci from Sichuan of China, panax notoginseng, baimianye, camphor, wallich pepper stem and leaf, philippine flemingia root, giant knotweed, sappanwood, rosewood, ciliate desert-grass and kusnezoff monkshood root; the Chinese herbal medicines and white spirit whose concentration is 50% are boiled for 40 minutes to be filtered to remove residues, and then, a medicinal liquor preparation is obtained. The medicinal liquor of the present invention has the functions of eliminating swelling, alleviating pain, activating channels and collaterals, activating blood circulation and dissipating blood stasis; the fractured bone has no need of being fixed by plaster, and only needs to be reset; medicinal cotton is soaked in the external medicinal liquor to be wetted, the medicinal cotton is pasted on the wound of a patient for 30 minutes every time, and then, the medicinal cotton is removed to achieve the purposes of quickly eliminating swelling and alleviating pain. The external medicinal liquor of the present invention has the advantages of convenient use, safety and no toxic or side effect, and has special effect on treatment of the fracture of patients; the course of treatment is short, and thus, the pain of patients having fracture is relieved. The external medicinal liquor is clinically used for many years to indicate that the healing rate reaches 90%. The external medicinal liquor is suitable for setting bones and treating traumatic injury and lumbar muscle strain.